Heldgaard P E, Griffin S J
Ørum Health Centre, Tjele, Denmark.
Diabet Med. 2006 Sep;23(9):996-1002. doi: 10.1111/j.1464-5491.2006.01929.x.
To assess the performance of a risk score comprising data routinely available in general practice records (age, gender, body mass index, family history of diabetes, smoking habits and prescribed anti-hypertensive drugs or steroids) in detecting diabetes, impaired glucose tolerance and metabolic syndrome.
In a population-based, cross-sectional study in a semi-rural general practice in Jutland, Denmark, Cambridge Risk Scores were calculated for 1355 patients without known diabetes (69% response rate) who completed questionnaires and underwent anthropometric measurement and an oral glucose tolerance test.
Prevalences of diabetes, impaired glucose tolerance and metabolic syndrome were 2.29% (95% CI: 1.56-3.23), 6.64% (95% CI: 5.38-8.10) and 13.4% (95% CI: 11.5-15.2), respectively. Area under the ROC curve for the risk score and diabetes was 83.8% (75.9-91.7) and for metabolic syndrome [European Group for the Study of Insulin Resistance (EGIR)] was 78.1% (74.6-81.6). Twenty per cent of the population had a risk score above 0.246; at this threshold the sensitivity to detect diabetes was 71.0% (53.4-83.9), the specificity 81.2% (79.0-83.2), positive predictive value 8.1% (6.6-10.0) and likelihood ratio 3.77 (2.94-4.85). For metabolic syndrome (EGIR) corresponding values for sensitivity were 50.3% (43.1-57.5), specificity 84.7% (82.5-85.6), positive predictive value 33.6% (28.2-39.4), and likelihood ratio 3.28 (2.69-4.00).
Undiagnosed hyperglycaemia and metabolic syndrome are common. The Cambridge Risk Score is a practical first step in a screening procedure to identify individuals with these disorders who might benefit from diagnostic testing or to direct preventive interventions.
评估一个由全科医疗记录中常规可得数据(年龄、性别、体重指数、糖尿病家族史、吸烟习惯以及处方的抗高血压药物或类固醇)组成的风险评分在检测糖尿病、糖耐量受损和代谢综合征方面的表现。
在丹麦日德兰半岛一个半乡村全科医疗所进行的一项基于人群的横断面研究中,为1355名无已知糖尿病的患者计算了剑桥风险评分(应答率69%),这些患者完成了问卷调查并接受了人体测量和口服葡萄糖耐量试验。
糖尿病、糖耐量受损和代谢综合征的患病率分别为2.29%(95%可信区间:1.56 - 3.23)、6.64%(95%可信区间:5.38 - 8.10)和13.4%(95%可信区间:11.5 - 15.2)。风险评分与糖尿病的ROC曲线下面积为83.8%(75.9 - 91.7),与代谢综合征[胰岛素抵抗研究欧洲组(EGIR)定义]的ROC曲线下面积为78.1%(74.6 - 81.6)。20%的人群风险评分高于0.246;在此阈值下,检测糖尿病的敏感性为71.0%(53.4 - 83.9),特异性为81.2%(79.0 - 83.2),阳性预测值为8.1%(6.6 - 10.0),似然比为3.77(2.94 - 4.85)。对于代谢综合征(EGIR),相应的敏感性值为50.3%(43.1 - 57.5),特异性为84.7%(82.5 - 85.6),阳性预测值为33.6%(28.2 - 39.4),似然比为3.28(2.69 - 4.00)。
未诊断的高血糖和代谢综合征很常见。剑桥风险评分是筛查程序中的一个实用的第一步,用于识别可能从诊断测试中获益或可接受预防性干预的患有这些疾病的个体。